Investigational antiviral drugs for the treatment of COVID-19

被引：0
|
作者：
Vegivinti, C. T. R. [1 ]
Assi, M. [2 ]
Talwani, R. [3 ]
Koblizek, V [4 ,5 ]
Burke, K. [6 ]
Temesgen, Z. [7 ]
机构：
[1] Manipal Acad Higher Educ MAHE, Kasturba Med Coll, Dept Gen Med, Manipal, Karnataka, India
[2] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA
[3] Univ Maryland, Div Infect Dis, Baltimore, MD 21201 USA
[4] Charles Univ Prague, Univ Hosp Hradec Kralove, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med, Prague, Czech Republic
[6] Wolters Kluwer, Clin Effectiveness, Indianapolis, IN USA
[7] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN USA
来源：
DRUGS OF THE FUTURE | 2021年 / 46卷 / 09期
基金：
美国国家卫生研究院;
关键词：
COVID-19; SARS-CoV-2; Remdesivir; Hydroxychloroquine; Lopinavir/ritonavir; Ribavirin; Ivermectin; Favipiravir; Umifenovir; Camostat; Nafamostat Nitazoxanide; DAS-181; RESPIRATORY SYNDROME CORONAVIRUS; SIALIDASE FUSION PROTEIN; NAFAMOSTAT MESILATE; INTERFERON-THERAPY; RIBAVIRIN; INHIBITOR; DAS181; IVERMECTIN; RITONAVIR; INFECTION;
D O I：
10.1358/dof.2021.46.9.3293585
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov , which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.
引用
收藏
页码：697 / 710
页数：14
相关论文
共 50 条
  • [41] COVID-19 Antiviral and Treatment Candidates: Current Status
    Espano, Erica
    Kim, Dajung
    Kim, Jiyeon
    Park, Song-Kyu
    Kim, Jeong-Ki
    IMMUNE NETWORK, 2021, 21 (01) : 1 - 24
  • [42] Triple antiviral treatment for COVID-19 in an immunocompromised patient
    Dentone, Chiara
    Mikulska, Malgorzata
    Sepulcri, Chiara
    Balletto, Elisa
    De Pace, Vanessa
    Beltramini, Sabrina
    Bassetti, Matteo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (08) : 2097 - 2099
  • [43] Potential of amentoflavone with antiviral properties in COVID-19 treatment
    Singh, Akhilesh Vikram
    ASIAN BIOMEDICINE, 2021, 15 (04) : 153 - 159
  • [44] Novel Antiviral Strategies in the Treatment of COVID-19: A Review
    Chen, Shiu-Jau
    Wang, Shao-Cheng
    Chen, Yuan-Chuan
    MICROORGANISMS, 2020, 8 (09) : 1 - 13
  • [45] Antiviral Drug Discovery for the Treatment of COVID-19 Infections
    Ng, Teresa, I
    Correia, Ivan
    Seagal, Jane
    DeGoey, David A.
    Schrimpf, Michael R.
    Hardee, David J.
    Noey, Elizabeth L.
    Kati, Warren M.
    VIRUSES-BASEL, 2022, 14 (05):
  • [46] Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19
    Abdellatiif, Magda H.
    Ali, Amena
    Ali, Abuzer
    Hussien, Mostafa A.
    OPEN CHEMISTRY, 2021, 19 (01): : 245 - 264
  • [47] Drugs for COVID-19 Treatment: A New Challenge
    Talukder, Pratik
    Saha, Arunima
    Roy, Sohini
    Ghosh, Gargi
    Roy, Debshikha Dutta
    Barua, Snejuti
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2023, 195 (06) : 3653 - 3670
  • [48] REPURPOSED DRUGS FOR TREATMENT AGAINST COVID-19
    Dwivedi, Jayati
    Singh, Vishal K.
    Raj, Rupa
    Singh, Ramendra K.
    EVERYMANS SCIENCE, 2021, 56 (3-4): : 95 - 100
  • [49] Drugs for COVID-19 Treatment: A New Challenge
    Pratik Talukder
    Arunima Saha
    Sohini Roy
    Gargi Ghosh
    Debshikha Dutta Roy
    Snejuti Barua
    Applied Biochemistry and Biotechnology, 2023, 195 : 3653 - 3670
  • [50] Repurposed GI Drugs in the Treatment of COVID-19
    Aguila, Enrik John T.
    Cua, Ian Homer Y.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (08) : 2452 - 2453
12345